Atogepant for the Prevention of Episodic Migraine in Adults
SAGE Open Medicine, 2022 Objective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant.
Kelsey Woods Morgan, Kayla R Joyner
exaly +4 more sources
Mass Balance and Metabolism of 14C-Atogepant in Healthy Male Participants: Findings of a Phase 1 Clinical Trial [PDF]
Clinical and Translational ScienceAtogepant, a calcitonin gene‐related peptide (CGRP) receptor antagonist, is approved for the preventive treatment of migraine in adults. This open‐label, phase 1 study examined radiolabeled atogepant (14C‐atogepant) metabolism, elimination, and mass ...
Joshua M Rowe, Ramesh R Boinpally
exaly +3 more sources
Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention [PDF]
The Journal of Headache and PainBackground Migraine is a leading cause of disability worldwide, impairing quality of life and productivity. Preventive therapies aim to reduce attack frequency, severity and the need for acute medications.
Simona Guerzoni +6 more
doaj +5 more sources
Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results From a Phase 1 Lactation Study [PDF]
Neurology and TherapyIntroduction Atogepant is approved for the preventive treatment of migraine and is taken orally once daily. This work aimed to characterize the plasma and milk pharmacokinetics of atogepant in lactating females.
Ramesh R Boinpally, Joel M Trugman
exaly +3 more sources
Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults
Neurology and TherapyIntroduction Atogepant is a calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine in adults in the USA, EU, and several other countries.
Ramesh R Boinpally
exaly +4 more sources
The role of Atogepant in migraine prevention: a systematic review and meta-analysis [PDF]
BMC NeurologyBackground Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.
Naresh Kumar Ladhwani +12 more
doaj +4 more sources
Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE [PDF]
Neurology and TherapyIntroduction Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention; however, real-world data from the Middle East and North Africa (MENA) region remain limited.
Taoufik Alsaadi +6 more
doaj +4 more sources
Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study [PDF]
Frontiers in NeurologyAimEpisodic Migraine (EM) is a highly prevalent and disabling neurological disorder. Recent therapeutic advances have targeted the calcitonin gene-related peptide (CGRP), a neuropeptide implicated in the pathophysiology of migraine.
Danilo Antonio Montisano +14 more
doaj +2 more sources
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans. [PDF]
Clin Transl SciABSTRACT The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants ( N = 28) were enrolled into this phase 1, open‐label study and received atogepant 60 mg once daily for 8 days.
Boinpally RR, Trugman JM.
europepmc +3 more sources
Population Pharmacokinetics of Atogepant for the Prevention of Migraine. [PDF]
Clin PharmacokinetAtogepant is an oral calcitonin gene-related peptide receptor antagonist developed for the preventive treatment of migraine. This work aimed to develop a population pharmacokinetic (popPK) model to support dosage regimen selection during the clinical development of atogepant in patients with episodic migraine (EM) or chronic migraine (CM) and to guide ...
Schlachter L +5 more
europepmc +3 more sources